Form 4: Cryo-Cell Director Acquires New Stock Options

Cryo-Cell International Inc. Director Daniel Mizrahi reported the acquisition of 5,300 new stock options with an exercise price of $4.35, vesting monthly from October 21, 2025.

Summary

• Daniel Mizrahi, a Director of Cryo-Cell International Inc. (CCEL), filed a Form 4 to report changes in beneficial ownership.
• The filing details the acquisition of 5,300 stock options on October 21, 2025.
• These newly acquired options have an exercise price of $4.35 per share.
• The options are scheduled to vest at a rate of 1/12 per month, commencing on October 21, 2025, and will expire on October 21, 2035.
• Mizrahi also directly beneficially owns 30,634 shares of common stock.
• He holds additional stock options from previous grants, including 5,300 options at $12.63 (expiring 10/20/2031), 5,300 options at $6.50 (expiring 10/03/2032), 5,300 options at $4.90 (expiring 10/10/2033), and 5,300 options at $5.82 (expiring 10/29/2034).

Sentiment

Score: 6

Explanation: The acquisition of new stock options by a director, especially with a vesting schedule, generally indicates continued commitment and belief in the company's future performance, which can be viewed as a positive signal by investors.

Positives

• Director Daniel Mizrahi acquired 5,300 new stock options, indicating continued alignment of his interests with shareholder value and potential confidence in the company's future.
• The exercise price of the new options ($4.35) is lower than several previous grants, which could suggest a belief in future stock appreciation from current levels.

Negatives

• No explicitly negative information is typically disclosed in a Form 4 filing, which primarily reports insider transactions.

Risks

• Form 4 filings primarily report insider transactions and do not typically detail company-specific risks or potential future challenges.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the vesting schedule and expiration dates of the stock options.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

Insider transactions, such as the acquisition of stock options by a director, are common events in publicly traded companies. These filings provide transparency into the equity holdings and compensation of key personnel. The acquisition of new options can be interpreted by the market as a sign of confidence in the company's future prospects, as the director's compensation becomes more aligned with stock performance.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions in the U.S. market, and the structure and content of this filing are consistent with SEC requirements.
• The grant of stock options as part of executive or director compensation is a widely adopted practice across various industries to incentivize long-term performance and align interests with shareholders. Specific comparable companies or projects are not relevant for this type of filing.

Related Party Transactions

• The stock option grant to a director is a related party transaction, which is a standard form of compensation and is disclosed as such in this filing. No other specific related party dealings are detailed.

Stakeholder Impact

• Shareholders: May view the director's acquisition of new stock options as a positive signal, indicating management's confidence in the company's future and aligning their interests with shareholder value.

Next Steps

• The newly acquired stock options will begin vesting at a rate of 1/12 per month commencing on October 21, 2025.

Key Dates

Keywords

Cryo-Cell International, CCEL, Daniel Mizrahi, Form 4, Insider Transaction, Stock Options, Director, Beneficial Ownership, Equity Compensation, SEC Filing